Urelumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Urelumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CD137
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6502H9972N1712O2030S44
Molar mass 145.8 kg/mol
 NYesY (what is this?)  (verify)

Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1]

Urelumab targets the extracellular domain of CD137.[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[3]

The first phase I trial began in 2006 and final results were published in 2015.[4]

Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.[5]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association. 
  2. ^ http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf
  3. ^ "Urelumab". National Cancer Institute. 
  4. ^ https://clinicaltrials.gov/ct2/show/NCT00309023?term=NCT00309023&rank=1
  5. ^ http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf